Advocacy News

October 27, 2015

IN THIS ISSUE

BACK TO MAIN

AAOS Sends Letters to Congress on HIT Issues

AOSSM President Testifies on Controlled Substances

Rep. Paul Ryan Speakership, Fall Agenda

Senate Hearing on Opioids, AAOS Approves Information Statement

What We’re Reading

Phentolamine Concerns Heard

ICYMI: Orthopaedic Surgeons Responds to IOAS Article

AAOS Orthopaedic PAC Online Contribution Center

 
MORE RESOURCES

AAOS website

AAOS Calendar

House of Representatives Legislative Activities
   
Facebook Twitter

 

Phentolamine Concerns Heard

imageThe American Association of Orthopaedic Surgeons joined eight orthopaedic specialty societies in sending a letter to the Acting FDA Commissioner Stephen M. Ostroff in April 2015, expressing concern over a nationwide shortage of phentolamine and asked FDA to post a letter on their drug shortage website stating that providers can seek out of country sources of this drug for their patients.

Phentolamine is the only alpha blocker that is an antagonist to adrenaline vasoconstriction. This is very important to hand surgeons and emergency room clinicians. Accidental EpiPen injections into fingers can cause ischemic changes for several hours and severe ischemic reperfusion pain for three months or more. Phentolamine has been shown to reliably reverse epinephrine vasoconstriction in the human finger, and is the antidote for prolonged epinephrine induced vasoconstriction caused by EpiPen injuries or wide awake hand surgery.

The last American supplier of phentolamine stopped its production in January 2015. Reserves of phentolamine could be found in Canada, available through Paladin Pharmaceuticals. However, it is illegal to import a drug into the United States from abroad unless the FDA posts a letter on their Drug Shortage website stating that health providers can seek out of country sources of drugs no longer available in the U.S.

FDA agreed to post a drug shortage letter for phentolamine on their website shortly after receiving the AAOS letter asking them to do so.

FDA subsequently worked with drug manufacturers and just notified AAOS that Westward Pharmaceuticals is planning to distribute phentolamine to pharmacies in the United States the first week of November. The Westward phentolamine injection is FDA-approved and pharmacies should be able to order this, using the NDC number on the FDA website, from their wholesalers the first week of November.

Information can be obtained at the following links:

Additional comments or questions can be sent to Captain Valerie Jensen R.Ph., Associate Director FDA CDER Drug Shortage Staff at Valerie.Jensen@fda.hhs.gov.